In the field of metabolic regulation drug development, is there a substance that can both mimic the health benefits of exercise and fasting while simultaneously protecting the function of multiple organs? ATX-304 is a promising oral small-molecule AMPK agonist, considered a potential drug candidate in the field of "metabolic enhancement." This article will provide more information about this compound.
What is ATX-304
ATX-304 powder, also known as O-304 , are an orally administered small-molecule AMPK activator. AMPK (adenosine monophosphate-activated protein kinase) is a key regulatory enzyme in cellular energy metabolism, sensing energy status and promoting fatty acid oxidation, glucose uptake, and mitochondrial function. This compound, by activating the adenosine kinase pathway, can improve insulin sensitivity, promote energy metabolism, reduce fat accumulation, and has shown cholesterol-lowering and fatty liver-improving effects in animal studies. Furthermore, it has renal protective effects, mitigating acute kidney injury induced by drugs such as cisplatin. Researchers believe it has the potential to mimic the metabolic benefits of exercise or fasting and is a promising candidate drug for "metabolic enhancement." Currently, it is mainly used in research on metabolic syndrome, obesity, type 2 diabetes, and related cardiovascular and kidney diseases. As one of the first orally administered, all-around AMPK activators, it opens up a new direction in the field of metabolic regulation drugs and is expected to be used in future research and treatment to delay metabolic decline, improve energy balance, and promote a healthy lifespan. If you are also interested in ATX-304, please feel free to contact Xi'an Sonwu. Xi'an Sonwu Company looks forward to your reply.
What does ATX-304 do
ATX-304 (also known as O-304) provides a range of potential benefits by activating AMP-activated protein kinase-a core regulator of cellular energy metabolism.
1. Improved Metabolic Health:
It enhances glucose uptake and insulin sensitivity, helping to stabilize blood sugar levels and combat insulin resistance-a key factor in type 2 diabetes and metabolic syndrome.
2. Promotes Fat Burning and Weight Control:
By stimulating AMP-activated protein kinase, it increases fatty acid oxidation and energy expenditure, thereby reducing body fat accumulation and improving lipid metabolism.
3. Liver Protection:
Animal studies have shown that it can lower blood cholesterol and reduce hepatic steatosis, suggesting potential benefits in the treatment of fatty liver disease (NAFLD/NASH).
4. Support for Kidney Function:
It has shown renal protective effects by enhancing mitochondrial activity and cell resilience, reducing acute kidney injury caused by nephrotoxic drugs such as cisplatin.
5. Improved Blood Circulation and Energy Utilization:
It enhances peripheral blood flow and muscle energy metabolism, potentially benefiting cardiovascular and muscle health, especially under metabolic and age-related conditions.
6. Benefits of mimicking exercise and calorie restriction: Because AMPK activation mimics the metabolic effects of exercise or fasting, it is being explored as a "metabolic amplifier" to improve healthy lifespan and resilience without lifestyle interventions.
It represents a promising next-generation metabolic therapy designed to treat obesity, diabetes, and related cardiovascular and kidney diseases by optimizing the body's natural energy-regulation pathways.
Is ATX-304 safe
The safety of ATX-304 is currently being evaluated through clinical trials. As of 2026, it is classified as an investigational drug.
1. Current Status of Clinical Safety
Human Trials: The compound has completed Phase I and Phase Ib clinical trials. Reports from these early stages indicate that the compound is well tolerated in healthy volunteers and patients with type 2 diabetes or obesity over a short period (up to 28 days).
Phase II Clinical Trials in Progress: The study is progressing to Phase II to evaluate its efficacy and safety over a longer period. A translational study completed in May 2025 specifically examined its pharmacokinetics and safety in obese and prediabetic patients.
2. Preclinical Safety Study Results
The effects of this compound on metabolic and cardiovascular disease have been tested using various animal models, primarily mice.
Liver and Metabolic Health: Studies published in 2024 and 2025 showed that it reduced oxidative stress and liver fibrosis in preclinical models, with no significant acute toxicity observed. Studies have shown that this compound is "peripherally restricted," meaning it is designed to act on tissues such as muscle and liver while avoiding entry into the central nervous system, potentially reducing the risk of neurological side effects.
3. Precautions
Because ATX-304 is a pan-AMPK activator (it activates all subtypes of the AMPK enzyme), researchers will monitor for specific "off-target" effects common to this type of drug:
Cardiac problems: The effects of long-term chronic AMPK activation on cardiometabolism remain controversial, but animal studies of this compound have actually shown it to improve cardiovascular function.
Muscle metabolism: Because it mimics some of the effects of exercise, scientists will monitor its effects on protein synthesis or muscle atrophy, but data from 2026 suggest it helps maintain lean body mass during weight loss.
Because this compound significantly affects glucose and lipid metabolism, it may interact with other metabolic drugs.
If you would like to inquire about the price of the ATX-304 capsule or other product information, please contact Xi'an Sonwu directly.
Email: sales@sonwu.com
References：https://feelgoodpal.com/blog/alfalfa/